9 result(s) displayed (1 - 9 of 9):

Glaxo closer to Dr. Reddy's buy-in? (from Corporate Dealmaker)

It makes sense that GlaxoSmithKline plc (NYSE:GSK) would emerge as the front-runner to acquire a stake in Indian drug giant Dr. Reddy's Laboratories Ltd. (NYSE:RDY). Citing people familiar with the matter, Reuters says that while nothing is finalized, one possibility is that Glaxo will take a 20% stake in Dr....

Posted on October 8, 2009 9:12 AM

Glaxo chief JV'ing his way to profits (from Corporate Dealmaker)

After watching his rivals consolidate and generic competition squeeze the company's earnings, GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty started allying to expand in emerging markets and shift money from pharmaceuticals into vaccines and consumer businesses.The latest deal is a revenue-sharing agreement with India's Dr. Reddy's Laboratories Ltd. (NYSE:RDY),...

Posted on June 16, 2009 12:52 PM

Glaxo making good on strategic shift (from Corporate Dealmaker)

As its first-quarter results were hammered by generic competition, GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty's game plan is to stay away from megamergers, expand in emerging markets and shift money from pharmaceuticals into vaccines and consumer businesses as more blockbuster drugs face generic competition. One such drug is its...

Posted on May 6, 2009 9:03 AM

Stiefel may keep acquiring as part of GSK (from Corporate Dealmaker)

GlaxoSmithKline plc (NYSE:GSK) is acquiring the world's largest independent dermatology company, Stiefel Laboratories Inc., for up to $3.6 billion. So far most reports have focused on Glaxo CEO Andrew Witty's strategy, which includes staying away from megamergers, expanding in emerging markets and shifting money from pharmaceuticals into vaccines and...

Posted on April 20, 2009 5:39 PM

Eli Lilly CEO talks of megamerger madness (from Corporate Dealmaker)

Eli Lilly & Co. (NYSE:LLY) CEO John Lechleiter (pictured) wants to stop the mega-merger madness. He told the Financial Times the recent big drug mergers are "driven more by weakness" and are short-term fixes that fail to address long-term productivity problems. He specifically rejected the idea of a combo with...

Posted on March 30, 2009 2:04 PM

Reports: Glaxo may acquire stake in Aspen Pharmacare (from Corporate Dealmaker)

News of pharma consolidation continued Thursday with various reports, including from The Wall Street Journal and Reuters, saying GlaxoSmithKline plc (NYSE:GSK) is in talks to acquire a minority stake in South African generic drugmaker Aspen Pharmacare Holdings Ltd. The Journal says Glaxo will likely buy 25% of Aspen, which has...

Posted on March 26, 2009 8:21 AM

Glaxo CEO says more on changing biz model, acquisitions (from Corporate Dealmaker)

GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty has said megamergers are a bad idea and that he likes being in consumer products (translation: look for bolt-on deals). More recently, at the Cowen & Co. healthcare conference in Boston, Witty (pictured) said Glaxo plans to shift money from its pharmaceuticals...

Posted on March 18, 2009 2:34 PM

Merck, Schering-Plough merge: Where do competitors stand? (from Corporate Dealmaker)

The trend of merging pharmas continued Monday with Merck & Co. (NYSE:MRK) and Schering-Plough Corp. (NYSE:SGP) announcing they would merge in a cash-and-stock deal worth $41.1 billion. The deal makes Merck the No. 2 drugmaker in the U.S. So what does that mean for  competitors like Bristol-Myers Squibb Co. and...

Posted on March 9, 2009 9:27 AM

GlaxoSmithKline says small companies want to be bought (from Corporate Dealmaker)

GlaxoSmithKline plc CEO Andrew Witty said small drug companies squeezed by the credit crunch are turning to GSK to discuss being acquired,  The Wall Street Journal reported. So GSK may step up its acquisition activity in the coming months. The pharma giant is already active. The Deal's Cheryl Meyer notes...

Posted on October 23, 2008 1:51 PM